MSK is proud to announce that four Sloan Kettering Institute (SKI) researchers have been named 2025 Marie-Josée Kravis Women ...

Learn how new research and clinical trials at Memorial Sloan Kettering Cancer Center (MSK) have helped 32-year-old Giancarlo ...

A phase 3 trial for myelofibrosis found that adding pelebresib to ruxolitinib was more effective than ruxolitinib alone and did not significantly increase side effects.

MSK researchers shed new light on G-quadruplexes, a type of secondary DNA structure that has attracted attention as a ...

Ready to start planning your care? Call us at 800-525-2225 to make an appointment.